Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Dana-Farber Cancer InstituteIn its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report.